Elevance Health stock trades around $400 as Q2 2026 earnings beat supports upbeat outlook
Published on 08/19/2026 at 18:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. (ISIN US2855211023) stock is trading close to the $400 mark as of August 19, 2026, with investors digesting a solid second-quarter 2026 earnings beat and a broadly positive full-year outlook.
Q2 2026 earnings beat underpins valuation
Per a recent earnings overview dated August 19, 2026, Elevance Health reported adjusted earnings per share of $7.45 for Q2 2026, significantly ahead of the $6.21 consensus estimate for the quarter. This same dataset shows Q2 2026 revenue of $50.47 billion and earnings of $1.46 billion, highlighting a quarter where profit expansion outpaced top-line growth.
A separate analyst-focused summary published on August 19, 2026 notes that Elevance Health generated Q2 2026 revenue of $49.83 billion versus analyst expectations of $48.88 billion, with the revenue figure up 0.8 percent year over year. The same report confirms that the company’s net margin stood at 2.47 percent and return on equity at 14.64 percent in the quarter, and that Q2 EPS of $7.45 exceeded the $6.21 consensus by $1.24.
In a broader healthcare comparison dated August 19, 2026, Elevance Health’s Q2 2026 results are characterized as a strong earnings print, with revenue flat at $49.83 billion versus the prior-year period but still surpassing forecasts by 2.5 percent. This sector-focused article underscores that EPS for the quarter beat analyst estimates and that full-year EPS guidance was in line with consensus expectations.
Consensus outlook and analyst targets
Consensus data compiled as of August 19, 2026 indicate that equities research teams expect Elevance Health to deliver earnings per share of 27.07 for the full year 2026, based on the latest forecasts that incorporate the Q2 2026 beat. A recent analysis points out that this 27.07 EPS expectation sits above trailing twelve-month earnings per share of 23.66 referenced in current market-data overviews, implying further EPS growth over the remainder of 2026.
The same consensus snapshots highlight that analyst assessments currently assign Elevance Health an overall rating in the Buy to Moderate Buy range, indicating that most covering analysts see upside from present levels. One detailed forecast page states that 23 research analysts have an average twelve-month stock price target of $440.90 for Elevance Health, with the high estimate at $498.00 and the low at $360.00.
Based on a fair-value snapshot timestamped August 19, 2026, this same forecast page cites a current reference price of $400.23 for Elevance Health stock and calculates that the $440.90 consensus target represents a projected upside of 10.16 percent from that level. A companion quote overview shows Elevance Health trading near $400 with a modest intraday gain, reinforcing that the stock price is broadly aligned with analyst expectations but still sits below the average target.
Share price performance and trading levels
Market-data pages updated on August 19, 2026 present several reference prices for Elevance Health stock around the $399 to $400 zone. One quote service records a closing price of $399.98 for Elevance Health Inc. on August 18, 2026 at 4:00 p.m. ET, with the move corresponding to a 2.50 percent gain for that session and a market capitalization of $86.37 billion.
A separate intraday trading update dated August 19, 2026 notes that Elevance Health stock opened at $399.35 on the New York Stock Exchange, with the company’s 50-day moving average price at $394.99 and its 200-day moving average price at $358.90. This institutional-position filing illustrates that recent gains have pulled the shares well above the longer-term moving average, a pattern that often signals sustained positive momentum.
Another real-time news feed for Elevance Health shows the stock quoted at around $399.02 with a small intraday increase of 0.19 percent as of 12:21 p.m. Eastern on August 19, 2026, underscoring the impression of a steady price around the $399 to $400 band. This news overview further associates the current trading level with ongoing reactions to earlier earnings developments and investor positioning.
Recent historical context indicates that Elevance Health’s share price has advanced from levels near $350.59 at the start of 2026 to the vicinity of $390 to $400 in mid-August 2026, equating to an increase of more than 11 percent year to date. A same-day analysis emphasizes that recent intraday ranges have seen the stock trade between the high $380s and just under $400, reflecting investor confidence driven by the Q2 earnings beat and guidance alignment.
Positioning within the healthcare sector
According to a healthcare sector comparison article dated August 19, 2026, Elevance Health is described as one of the largest health insurers in the United States, serving around 47 million medical members through network-based managed care plans. This sector overview reports that the company ended Q2 2026 with 44.95 million customers after losing 469,000 customers during the period, a reminder that membership trends remain a key metric for investors even when earnings are strong.
The same comparison notes that Elevance Health’s Q2 2026 revenue of $49.83 billion was flat year on year but still met or exceeded expectations, while EPS strength and aligned full-year guidance kept the overall narrative favorable. When set against peers facing greater reimbursement or utilization pressures, Elevance Health’s ability to beat earnings estimates while delivering stable revenue highlights operational resilience, although the modest membership decline signals that competitive dynamics in US health insurance remain intense.
Institutional activity reported on August 19, 2026 reinforces this view of Elevance Health as an attractive large-cap healthcare holding. One filing overview documents a new $27.83 million investment by a major pension provider, highlighting that sizable long-term investors are increasing exposure to the stock as the company executes on its earnings and guidance framework.
Representative product and business focus
In Elevance Health’s business model, a central pillar is its suite of commercial and government health plans that provide medical coverage to millions of US members, often layered with care management and wellness programs. These offerings are designed to integrate traditional insurance benefits with tools that help members manage chronic conditions, coordinate care across providers and access digital health services, reflecting a broader industry shift toward outcomes-focused, value-based healthcare arrangements.
Price context for Elevance Health stock
As of the most recent completed New York trading session on August 18, 2026 at 4:00 p.m. ET, market-data pages report a closing price of $399.98 for Elevance Health stock, with the shares continuing to trade close to that level in intraday snapshots on August 19, 2026.
Fact box
Company: Elevance Health Inc.
ISIN: US2855211023
Ticker: ELV
Exchange: NYSE
Price (as of August 18, 2026, 4:00 p.m. ET): $399.98 USD
Market cap: $86.37 billion (as of August 18, 2026)
Sector / Industry: Health care / Managed care
Index membership: S&P 500
